Home About us Articles Multimedia Search Instructions Login 
IF 2017: 1.596 (® Clarivate Analytics)
Total Cites: 7606
Q2 in Medicine, General & Internal
Follow Us
Follow Us
  • Users Online: 495
  • Home
  • Print this page
  • Email this page
Year : 2018  |  Volume : 131  |  Issue : 10  |  Page : 1151-1157

Antibiotics De-Escalation in the Treatment of Ventilator-Associated Pneumonia in Trauma Patients: A Retrospective Study on Propensity Score Matching Method

Department of Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China

Correspondence Address:
Dr. Jian-Guo Tang
Department of Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0366-6999.231529

Rights and Permissions

Background: Antimicrobial de-escalation refers to starting the antimicrobial treatment with broad-spectrum antibiotics, followed by narrowing the drug spectrum according to culture results. The present study evaluated the effect of de-escalation on ventilator-associated pneumonia (VAP) in trauma patients. Methods: This retrospective study was conducted on trauma patients with VAP, who received de-escalation therapy (de-escalation group) or non-de-escalation therapy (non-de-escalation group). Propensity score matching method was used to balance the baseline characteristics between both groups. The 28-day mortality, length of hospitalization and Intensive Care Unit stay, and expense of antibiotics and hospitalization between both groups were compared. Multivariable analysis explored the factors that influenced the 28-day mortality and implementation of de-escalation. Results: Among the 156 patients, 62 patients received de-escalation therapy and 94 patients received non-de-escalation therapy. No significant difference was observed in 28-day mortality between both groups (28.6% vs. 23.8%, P = 0.620). The duration of antibiotics treatment in the de-escalation group was shorter than that in the non-de-escalation group (11 [8–13] vs. 14 [8–19] days, P = 0.045). The expenses of antibiotics and hospitalization in de-escalation group were significantly lower than that in the non-de-escalation group (6430 ± 2730 vs. 7618 ± 2568 RMB Yuan, P = 0.043 and 19,173 ± 16,861 vs. 24,184 ± 12,039 RMB Yuan, P = 0.024, respectively). Multivariate analysis showed that high Acute Physiology and Chronic Health Evaluation II (APACHE II) score, high injury severity score, multi-drug resistant (MDR) infection, and inappropriate initial antibiotics were associated with patients' 28-day mortality, while high APACHE II score, MDR infection and inappropriate initial antibiotics were independent factors that prevented the implementation of de-escalation. Conclusions: De-escalation strategy in the treatment of trauma patients with VAP could reduce the duration of antibiotics treatments and expense of hospitalization, without increasing the 28-day mortality and MDR infection.


 Abstract in Chinese





结果:共有156例患者纳入研究,其中62例接受抗生素降阶梯治疗,94例未接受抗生素降阶梯治疗。两组患者的28天死亡率未见明显差异(28.6% vs. 23.8%, P=0.620)。降阶梯治疗组患者的抗生素使用时间短于非降阶梯治疗组(11 (8–13) vs. 14 (8–19) days, P=0.045),并且降阶梯治疗组患者的抗生素使用费用和住院总费用低于非降阶梯治疗组(6430 ± 2730 vs. 7618 ± 2568 元人民币, P = 0.043 and 19,173 ± 16,861 vs. 24,184 ± 12,039 元人民币, P = 0.024)。多元分析提示患者的高APACHE II评分、高ISS评分、多重耐药菌感染和不恰当的起始抗感染治疗与患者的28天死亡率相关,而高APACHE II评分、多重耐药菌感染和不恰当的起始抗感染治疗是影响抗生素降阶梯的独立危险因素。


Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded253    
    Comments [Add]    

Recommend this journal